A Phase IB Study to Evaluate the Safety and Feasibility of Nivolumab or Nivolumab With Azacitidine in Patients With Recurrent, Resectable Osteosarcoma: A Report From the National Pediatric Cancer Foundation

Background Relapse rates following complete surgical resection (CSR) of pulmonary osteosarcoma recurrence remain high. We hypothesized that PD‐1 inhibition with nivolumab (Nivo) combined with epigenetic priming using azacitidine (5‐Aza) would be safe and augment systemic immune activation in patients with resectable pulmonary osteosarcoma relapse. Methods This Phase I trial sought to establish the recommended Phase II dose (RP2D) of perioperative Nivo/5‐Aza in patients ≤39 years old with isolated, resectable pulmonary osteosarcoma relapse. Three dose levels (DLs) were studied using a modified 3 + 3 design with dose‐limiting toxicities (DLTs) assessed from Day 1 of therapy to CSR. Patients received biweekly Nivo 3 mg/kg alone (DL1) or with 5‐Aza at 60 or 75 mg/m 2 /day (DL2 and DL3) in 28‐day cycles. Results Twenty patients received therapy; 18 were evaluable for DLTs. DL3 exceeded the maximum tolerated dose (Grade 3 vomiting, prolonged Grade 4 neutropenia). Common adverse events included anemia, neutropenia, and nausea. Seventeen patients (85%) reached CSR after neoadjuvant therapy. Median event‐free survival (EFS) was 3.3 months (95% confidence interval [CI]: 1.7–7.7 months), and median overall survival was 21.1 months (95% CI: 10.1–42.6 months). Combination therapy was associated with evidence of systemic immune activation, including increases in IFN‐γ, IL‐1α, IL‐1β, and CCL5. Conclusion The RP2D was Nivo 3 mg/kg and 5‐Aza 60 mg/m 2 /day on Days 1–5 and 8–9. The combination was feasible and tolerable. EFS was limited in the context of a Phase I trial. These findings provide safety, feasibility, and exploratory immunologic data to inform future immunotherapy trials in osteosarcoma.

Authors

Institutions

Publication Details

Journal
Pediatric Blood & Cancer
Published
2026-11-20
DOI
https://doi.org/10.1002/1545-5017.70815
Primary Topic
Sarcoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A Phase IB Study to Evaluate the Safety and Feasibility of Nivolumab or Nivolumab With Azacitidine in Patients With Recurrent, Resectable Osteosarcoma: A Report From the National Pediatric Cancer Foundation

Brooke L. Fridley, Eric S. Sandler, Michael S. Isakoff, Damon R. Reed et al.
1 links
Pediatric Blood & Cancer
Sarcoma Diagnosis and Treatment
article

A Phase IB Study to Evaluate the Safety and Feasibility of Nivolumab or Nivolumab With Azacitidine in Patients With Recurrent, Resectable Osteosarcoma: A Report From the National Pediatric Cancer Foundation

Brooke L. Fridley, Eric S. Sandler, Michael S. Isakoff, Damon R. Reed, Brian H. Ladle, Alexandre Maalouf, Kaushal Sharma, Nicolas Jose Llosa, Joanne Lagmay, Ajay Kumar Gupta, Lars M. Wagner, Mihaela Druta, Jessica Crimella, Scott C. Borinstein, Bhuvana A. Setty, Junmin Whiting, Jun Yin, Patrick A. Thompson, Matteo M. Trucco, Thomas Badgett, Matthew E. Campbell, Jonathan Metts, Aditya Suru, Javier Oesterheld
article en

Abstract

Background Relapse rates following complete surgical resection (CSR) of pulmonary osteosarcoma recurrence remain high. We hypothesized that PD‐1 inhibition with nivolumab (Nivo) combined with epigenetic priming using azacitidine (5‐Aza) would be safe and augment systemic immune activation in patients with resectable pulmonary osteosarcoma relapse. Methods This Phase I trial sought to establish the recommended Phase II dose (RP2D) of perioperative Nivo/5‐Aza in patients ≤39 years old with isolated, resectable pulmonary osteosarcoma relapse. Three dose levels (DLs) were studied using a modified 3 + 3 design with dose‐limiting toxicities (DLTs) assessed from Day 1 of therapy to CSR. Patients received biweekly Nivo 3 mg/kg alone (DL1) or with 5‐Aza at 60 or 75 mg/m 2 /day (DL2 and DL3) in 28‐day cycles. Results Twenty patients received therapy; 18 were evaluable for DLTs. DL3 exceeded the maximum tolerated dose (Grade 3 vomiting, prolonged Grade 4 neutropenia). Common adverse events included anemia, neutropenia, and nausea. Seventeen patients (85%) reached CSR after neoadjuvant therapy. Median event‐free survival (EFS) was 3.3 months (95% confidence interval [CI]: 1.7–7.7 months), and median overall survival was 21.1 months (95% CI: 10.1–42.6 months). Combination therapy was associated with evidence of systemic immune activation, including increases in IFN‐γ, IL‐1α, IL‐1β, and CCL5. Conclusion The RP2D was Nivo 3 mg/kg and 5‐Aza 60 mg/m 2 /day on Days 1–5 and 8–9. The combination was feasible and tolerable. EFS was limited in the context of a Phase I trial. These findings provide safety, feasibility, and exploratory immunologic data to inform future immunotherapy trials in osteosarcoma.

Pediatric Blood & Cancer
University of North Carolina at Chapel Hill (US), Roswell Park Comprehensive Cancer Center (US), Nationwide Children's Hospital (US), Cleveland Clinic (US), Children's Mercy Hospital (US), UF Health Shands Hospital (US), University of Kentucky (US), Johns Hopkins University (US), Duke University (US), Vanderbilt University (US), University of Florida Health (US), Carolinas Medical Center (US), Moffitt Cancer Center (US), University of Florida (US), Johns Hopkins All Children's Hospital (US), Levine Cancer Institute (US), Connecticut Children's Medical Center (US), Nemours Children's Health System (US), Vanderbilt-Ingram Cancer Center (US), The University of Texas Southwestern Medical Center (US)
Bristol-Myers Squibb, Florida Department of Health, Moffitt Cancer Center, National Cancer Institute
Good health and well-being
Sarcoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon